Vietnamese rituximab biosimilar boost brings more good news to Biocad expansion plans

30 March 2017

International expansion and bringing affordable biosimilars to patients are two of the stated aims of privately-held Russian biotech company Biocad, and the company has taken a step forward on both fronts with news on one of its products.

A decision in Vietnam means Biocad can continue to supply its patients with a biosimilar version of rituximab, a monoclonal antibody to the CD20 protein, approved for the treatment of non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia, as well as other diseases characterized by excessive, overactive or dysfunctional B cells. The branded version is sold by Swiss pharma giant Roche (ROG: SIX) under the names MabThera and Rituxan.

Biocad expects to receive a permanent registration certificate to sell its biosimilar in Vietnam later this year, allowing the company to export the product from Russia without any limitations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK